[
  {
    "ts": null,
    "headline": "Closing Bell Movers: Amazon soars to all-time highs on earnings",
    "summary": "In the opening hour of the evening session, U.S. equity futures are notably higher, with S&P 500 up 0.5% and Nasdaq 100 contracts up 1.0%. In commodities, WTI Crude Oil is little changed just above $60 per barrel while precious metals are stronger for the 3rd day in a row – Gold is above $4,040 and Silver is approaching $49 per ounce. A strong slate of quarterly Tech results are helping stock futures restore positive sentiment in the segment that was wounded on Thursday by more dubious results o",
    "url": "https://finnhub.io/api/news?id=3a1414e7215f21517b4d9eda8279f4f818c5451572e22aedcf307017745338b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761953738,
      "headline": "Closing Bell Movers: Amazon soars to all-time highs on earnings",
      "id": 137286030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In the opening hour of the evening session, U.S. equity futures are notably higher, with S&P 500 up 0.5% and Nasdaq 100 contracts up 1.0%. In commodities, WTI Crude Oil is little changed just above $60 per barrel while precious metals are stronger for the 3rd day in a row – Gold is above $4,040 and Silver is approaching $49 per ounce. A strong slate of quarterly Tech results are helping stock futures restore positive sentiment in the segment that was wounded on Thursday by more dubious results o",
      "url": "https://finnhub.io/api/news?id=3a1414e7215f21517b4d9eda8279f4f818c5451572e22aedcf307017745338b6"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot",
    "summary": "Gilead stock reversed higher on smaller losses early Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot.",
    "url": "https://finnhub.io/api/news?id=c04d2cb5762813c8f82be8ddb1a79eb355dd379ea850167efff9920c65c6c976",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761922385,
      "headline": "Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot",
      "id": 137279201,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead stock reversed higher on smaller losses early Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot.",
      "url": "https://finnhub.io/api/news?id=c04d2cb5762813c8f82be8ddb1a79eb355dd379ea850167efff9920c65c6c976"
    }
  },
  {
    "ts": null,
    "headline": "GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow",
    "summary": "Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.",
    "url": "https://finnhub.io/api/news?id=56c1428bc404a1cb73d6f00e3e2a05eda5b191a0166d484beba6819a82284355",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761920400,
      "headline": "GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow",
      "id": 137279202,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.",
      "url": "https://finnhub.io/api/news?id=56c1428bc404a1cb73d6f00e3e2a05eda5b191a0166d484beba6819a82284355"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=bcec1e6c4ce27cc2cecb4a4180abb21a3473ef786278ec20d26bab1317bcd087",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761915602,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 137279203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=bcec1e6c4ce27cc2cecb4a4180abb21a3473ef786278ec20d26bab1317bcd087"
    }
  },
  {
    "ts": null,
    "headline": "GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=d49647575f28c9214f08724918db4dbccc40680ee1d0f7befa22f0c7b90aa88e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761914445,
      "headline": "GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds",
      "id": 137279204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=d49647575f28c9214f08724918db4dbccc40680ee1d0f7befa22f0c7b90aa88e"
    }
  },
  {
    "ts": null,
    "headline": "HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead",
    "summary": "NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”). In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Pu",
    "url": "https://finnhub.io/api/news?id=c79a8f09f864d3307cff2c0ac0daeb6a12e68252c39428f58982a8afe2e5d611",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761912000,
      "headline": "HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead",
      "id": 137277401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”). In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Pu",
      "url": "https://finnhub.io/api/news?id=c79a8f09f864d3307cff2c0ac0daeb6a12e68252c39428f58982a8afe2e5d611"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)",
    "summary": "FOSTER CITY, Calif., October 31, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company’s twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure prophylaxis (PrEP) for the prevention of HIV. The award, which recognizes outstanding pharmaceuti",
    "url": "https://finnhub.io/api/news?id=2e722b39cbc87eda4ed93187b50e9892e0ae10719fc89f45e5ffb6029f5b7d56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761912000,
      "headline": "Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)",
      "id": 137277400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., October 31, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company’s twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure prophylaxis (PrEP) for the prevention of HIV. The award, which recognizes outstanding pharmaceuti",
      "url": "https://finnhub.io/api/news?id=2e722b39cbc87eda4ed93187b50e9892e0ae10719fc89f45e5ffb6029f5b7d56"
    }
  },
  {
    "ts": null,
    "headline": "Is Wall Street Bullish or Bearish on Gilead Sciences Stock?",
    "summary": "Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.",
    "url": "https://finnhub.io/api/news?id=e009582b60a59065bce9587a9dd840f91e77171368a7d08392282b6f3397f127",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761903887,
      "headline": "Is Wall Street Bullish or Bearish on Gilead Sciences Stock?",
      "id": 137277402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.",
      "url": "https://finnhub.io/api/news?id=e009582b60a59065bce9587a9dd840f91e77171368a7d08392282b6f3397f127"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc (GILD) Q3 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...",
    "summary": "Gilead Sciences Inc (GILD) reports robust performance in HIV therapies, offsetting challenges in Veklury and cell therapy sales.",
    "url": "https://finnhub.io/api/news?id=18e1bd4657b07877bfd700de8e1ab0539d8d5eaa2c4195da771d43c0f3eda61d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761879657,
      "headline": "Gilead Sciences Inc (GILD) Q3 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...",
      "id": 137275122,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences Inc (GILD) reports robust performance in HIV therapies, offsetting challenges in Veklury and cell therapy sales.",
      "url": "https://finnhub.io/api/news?id=18e1bd4657b07877bfd700de8e1ab0539d8d5eaa2c4195da771d43c0f3eda61d"
    }
  }
]